A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CHAMPIONS ONCOLOGY, INC.
CSBR
$87M
Mkt Cap
$6.13
+2.17%
CHAMPIONS ONCOLOGY, INC. (CSBR) has a current P/E ratio of 36.1, compared to its historical median P/E of 22.2. The stock is currently considered Expensive based on its historical valuation range.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a 5-year average return on invested capital (ROIC) of -2.2%. This is below average and may indicate limited pricing power.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a market capitalization of $85M. It is classified as a small-cap stock.
CHAMPIONS ONCOLOGY, INC. (CSBR) does not currently pay a regular dividend.
Based on historical P/E analysis, CHAMPIONS ONCOLOGY, INC. (CSBR) appears expensive. The current P/E of 36.1 is 63% above its historical median of 22.2. The estimated fair value CAGR (P/E method) is 69.6%.
CHAMPIONS ONCOLOGY, INC. (CSBR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
CHAMPIONS ONCOLOGY, INC. (CSBR) reported annual revenue of $57 million in its most recent fiscal year, based on SEC EDGAR filings.
We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 58M | 57M | 50M | 54M | 49M | 41M |
| Net Income | -2.3M | 4.7M | -7.3M | -5.3M | 548K | 362K |
| EPS | $-0.17 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 |
| Free Cash Flow | 3.8M | 7.0M | -7.0M | 1.1M | 4.1M | -5.0M |
| ROIC | -7.3% | 14.3% | -22.2% | -12.1% | 354.4% | 11.1% |
| Gross Margin | - | 50.1% | 41.4% | 45.2% | 51.9% | 47.7% |
| Debt/Equity | 0.02 | 0.06 | -14.73 | 0.03 | 0.01 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -2.6M | 4.6M | -7.4M | -5.3M | 607K | 366K |
| Operating Margin | -4.5% | 8.0% | -14.7% | -9.8% | 1.2% | 0.9% |
| ROE | -54.7% | 124.6% | - | -77.7% | 6.6% | 5.8% |
| Shares Outstanding | 14M | 14M | 13M | 14M | 14M | 18M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 12M | 8.9M | 11M | 15M | 20M | 27M | 32M | 41M | 49M | 54M | 50M | 57M | 58M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 47.1% | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% | N/A |
| R&D | 2.3M | 4.8M | 4.2M | 4.3M | 4.4M | 4.8M | 5.9M | 7.2M | 9.4M | 12M | 9.5M | 6.8M | 8.9M |
| SG&A | 6.1M | 5.3M | 5.2M | 5.0M | 4.1M | 4.7M | 6.6M | 6.5M | 9.1M | 10M | 11M | 9.3M | 11M |
| EBIT | -6.3M | -13M | -10M | -6.8M | -1.4M | 270K | -1.9M | 366K | 607K | -5.3M | -7.4M | 4.6M | -2.6M |
| Op. Margin | -54.2% | -149.4% | -92.3% | -44.2% | -6.7% | 1.0% | -6.0% | 0.9% | 1.2% | -9.8% | -14.7% | 8.0% | -4.5% |
| Net Income | -7.4M | -13M | -10M | -6.9M | -1.5M | 128K | -2.1M | 362K | 548K | -5.3M | -7.3M | 4.7M | -2.3M |
| Net Margin | -64.1% | -148.3% | -93.4% | -44.7% | -7.3% | 0.5% | -6.5% | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% | -4.0% |
| Non-Recurring | 0 | -5K | 0 | 0 | 3K | 0 | 387K | 0 | 4K | 0 | -435K | -293K | -293K |
| Returns on Capital | |||||||||||||
| ROIC | -154.7% | -129.8% | N/M | N/M | N/M | 7.0% | -7.3% | 11.1% | N/M | -12.1% | -22.2% | 14.3% | -7.3% |
| ROE | 246.5% | -233.5% | -251.8% | -1721.0% | -49200.0% | 12.0% | -57.8% | 5.8% | 6.6% | -77.7% | N/A | 124.6% | -54.7% |
| ROA | -72.2% | -125.7% | -117.2% | -99.9% | -18.3% | 1.3% | -13.1% | 1.5% | 1.7% | -15.3% | -24.1% | 16.1% | -8.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -3.4M | -9.6M | -6.4M | -2.8M | -1.2M | 1.9M | 2.9M | -1.7M | 6.5M | 4.0M | -6.1M | 7.4M | 4.4M |
| Free Cash Flow | -3.7M | -9.7M | -6.7M | -3.6M | -2.5M | 1.0M | 685K | -5.0M | 4.1M | 1.1M | -7.0M | 7.0M | 3.8M |
| Owner Earnings | -6.5M | -13M | -9.2M | -5.7M | -2.6M | 620K | 1.5M | -3.2M | 4.1M | 1.0M | -9.2M | 5.1M | 1.9M |
| CapEx | 234K | 119K | 322K | 766K | 1.2M | 834K | 2.2M | 3.3M | 2.4M | 2.9M | 836K | 389K | 578K |
| Maint. CapEx | 213K | 214K | 156K | 168K | 360K | 606K | 825K | 925K | 1.5M | 2.1M | 1.9M | 1.6M | 1.5M |
| Growth CapEx | 21K | 0 | 166K | 598K | 869K | 228K | 1.4M | 2.4M | 884K | 772K | 0 | 0 | 0 |
| D&A | 213K | 214K | 156K | 168K | 360K | 606K | 825K | 925K | 1.5M | 2.1M | 1.9M | 1.6M | 1.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 44.8% | 76.4% | N/A | 36.7% | 72.3% | N/A | 5.3% | 13.2% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74K | 634K | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.1% | 0.9% | N/A | 0.0% |
| Stock-Based Comp | 2.8M | 3.2M | 2.6M | 2.7M | 1.0M | 636K | 600K | 598K | 912K | 864K | 1.1M | 654K | 1.0M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -8.2M | -4.7M | -8.9M | -10.0M | N/A | -9.6M | -7.0M |
| Cash & Equiv. | 5.9M | 9.4M | 2.6M | 3.3M | 856K | 3.2M | 8.3M | 4.7M | 9.0M | 10M | 2.6M | 9.8M | 7.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 85K | 27K |
| Debt/Equity | 1.77 | 0.49 | 23.27 | 19.03 | 2691.67 | 4.22 | 0.02 | 0.00 | 0.01 | 0.03 | -14.73 | 0.06 | 0.02 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A | -0.1 | 0.1 | N/A | N/A | N/A | N/A | N/A |
| Equity | 3.2M | 8.1M | 238K | 400K | 3K | 2.1M | 5.1M | 7.4M | 9.1M | 4.6M | -1.9M | 3.8M | 4.3M |
| Total Assets | 8.9M | 12M | 5.8M | 8.0M | 8.1M | 11M | 21M | 28M | 35M | 34M | 26M | 32M | 28M |
| Total Liabilities | 5.7M | 4.0M | 5.5M | 7.6M | 8.1M | 9.0M | 16M | 20M | 26M | 30M | 28M | 29M | 24M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -39M | -52M | -62M | -69M | -71M | -71M | -73M | -73M | -72M | -77M | -85M | -80M | -80M |
| Working Capital | 3.9M | 7.0M | -966K | -1.6M | -2.4M | -103K | 1.2M | 1.4M | 2.2M | -2.3M | -7.9M | -1.5M | -492K |
| Current Assets | 7.6M | 11M | 4.3M | 5.9M | 5.1M | 7.9M | 13M | 13M | 20M | 19M | 14M | 22M | 20M |
| Current Liabilities | 3.7M | 3.8M | 5.3M | 7.4M | 7.5M | 8.0M | 12M | 11M | 17M | 22M | 22M | 24M | 21M |
| Per Share Data | |||||||||||||
| EPS | -1.32 | -26.40 | -1.20 | -0.64 | -0.13 | 0.01 | -0.18 | 0.02 | 0.04 | -0.39 | -0.54 | 0.33 | -0.17 |
| Owner EPS | -1.15 | -26.13 | -1.05 | -0.53 | -0.23 | 0.05 | 0.13 | -0.18 | 0.30 | 0.07 | -0.68 | 0.36 | 0.14 |
| Book Value | 0.57 | 16.19 | 0.03 | 0.04 | 0.00 | 0.17 | 0.44 | 0.41 | 0.66 | 0.34 | -0.14 | 0.26 | 0.31 |
| Cash Flow/Share | -0.61 | -19.35 | -0.74 | -0.26 | -0.11 | 0.15 | 0.25 | -0.09 | 0.47 | 0.29 | -0.46 | 0.52 | -0.06 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 5.6M | 0.5M | 8.7M | 10.8M | 11.4M | 12.8M | 11.6M | 18.1M | 13.7M | 13.7M | 13.5M | 14.2M | 13.9M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 890.0 | N/A | 534.0 | 197.7 | N/A | N/A | 22.2 | -36.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | 110.8 | 128.3 | N/A | 26.3 | 61.2 | N/A | 14.9 | 22.3 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 21.5 | 5.3 | 140.8 | 71.3 | N/A | N/A | 17.2 | 26.0 | 11.9 | 14.5 | N/A | 27.6 | 19.9 |
| Price/Sales | 6.4 | 5.6 | 3.9 | 1.8 | 1.9 | N/A | 2.5 | 4.5 | 2.6 | 1.6 | 1.5 | 1.6 | 1.5 |
| FCF Yield | -5.3% | -22.7% | -20.1% | -12.7% | -4.8% | N/A | 0.8% | -2.6% | 3.8% | 1.6% | -10.3% | 6.7% | 4.5% |
| Market Cap | 69M | 43M | 34M | 29M | 51M | N/A | 88M | 193M | 108M | 67M | 68M | 104M | 85M |
| Avg. Price | 13.12 | 8.37 | 5.07 | 2.59 | 3.32 | 9.14 | 7.00 | 10.10 | 9.16 | 6.48 | 5.74 | 6.35 | 6.13 |
| Year-End Price | 12.24 | 7.20 | 3.85 | 2.65 | 4.49 | 8.90 | 7.56 | 10.68 | 7.91 | 4.92 | 5.02 | 7.31 | 6.13 |
CHAMPIONS ONCOLOGY, INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
CHAMPIONS ONCOLOGY, INC. trades at 36.1x trailing earnings, compared to its 15-year median P/E of 22.2x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 15.1x vs a median of 26.3x. The company's 5-year average gross margin is 47.3%. At current prices, the estimated annualized return to fair value is +66.5%.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a net profit margin of 8.3%. This is a modest margin.
CHAMPIONS ONCOLOGY, INC. (CSBR) generated $7 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
CHAMPIONS ONCOLOGY, INC. (CSBR) reported earnings per share (EPS) of $0.33 in its most recent fiscal year.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a return on equity (ROE) of 124.6%. This indicates the company generates strong returns for shareholders.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a 5-year average gross margin of 47.3%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for CHAMPIONS ONCOLOGY, INC. (CSBR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CHAMPIONS ONCOLOGY, INC. (CSBR) has a book value per share of $0.26, based on its most recent annual SEC filing.